Side Effects of Irbesartan
Irbesartan is generally well-tolerated with a safety profile similar to placebo, but key side effects include hyperkalemia (especially in patients with chronic kidney disease or those on potassium supplements), risk of acute renal failure in bilateral renal artery stenosis, hypotension in volume-depleted patients, and potential for angioedema (though less common than with ACE inhibitors). 1
Critical Safety Warnings
Pregnancy - Category D
- Discontinue irbesartan immediately when pregnancy is detected 1
- Use during second and third trimesters causes:
- Fetal renal dysfunction
- Oligohydramnios
- Fetal lung hypoplasia and skeletal deformations
- Neonatal skull hypoplasia, anuria, hypotension, renal failure, and death
- Monitor infants with in utero exposure for hypotension, oliguria, and hyperkalemia 1
Renal Effects
- Increased risk of hyperkalemia, particularly in patients with:
- Risk of acute renal failure in patients with severe bilateral renal artery stenosis 2, 3, 1
- Monitor renal function periodically; consider withholding therapy if clinically significant decline occurs 1
Cardiovascular Effects
- Symptomatic hypotension may occur in volume- or salt-depleted patients (e.g., those on high-dose diuretics) 1
- Correct volume depletion before initiating therapy or use lower starting dose 1
Common Side Effects
Peripheral Edema
- Most frequent adverse event, particularly when combined with amlodipine 4
- Dose-related and more common in women than men 2, 3
- Rare cases of persistent facial, periorbital, and neck edema have been reported 5
Angioedema
- Do not use if patient has history of angioedema with ARBs 2, 3
- Patients with prior ACE inhibitor-related angioedema can receive irbesartan beginning 6 weeks after ACE inhibitor discontinuation 2, 3
Sexual Dysfunction
- Recent pharmacovigilance data suggests significant association with erectile dysfunction (ROR = 3.38,95% CI: 2.36-4.84) 6
- Consider monitoring for this potential adverse effect in male patients
Drug Interactions and Contraindications
Simultaneous use of ACE inhibitor, ARB, and/or renin inhibitor is potentially harmful and not recommended - this combination increases risk without additional benefit 2, 3
Tolerability Profile
- Overall adverse event frequency similar to placebo in most studies 7
- Most treatment-emergent adverse events are mild to moderate in severity 4
- Excellent safety profile ensures high patient compliance 8
- In pediatric studies (ages 4-17 years), frequency of adverse events was similar before and during irbesartan treatment 9
Special Populations
Geriatric Patients
- No overall differences in safety observed in patients ≥65 years, though greater sensitivity in some individuals cannot be ruled out 1
Nursing Mothers
- Discontinue nursing or discontinue irbesartan, as it is secreted in rat milk and potential effects on human infants are unknown 1